JP2024522065A5 - - Google Patents

Info

Publication number
JP2024522065A5
JP2024522065A5 JP2023571283A JP2023571283A JP2024522065A5 JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5 JP 2023571283 A JP2023571283 A JP 2023571283A JP 2023571283 A JP2023571283 A JP 2023571283A JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disorder
polymer
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/063269 external-priority patent/WO2022243285A1/en
Publication of JP2024522065A publication Critical patent/JP2024522065A/ja
Publication of JP2024522065A5 publication Critical patent/JP2024522065A5/ja
Pending legal-status Critical Current

Links

JP2023571283A 2021-05-17 2022-05-17 シロシビンの製剤 Pending JP2024522065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189449P 2021-05-17 2021-05-17
US63/189,449 2021-05-17
PCT/EP2022/063269 WO2022243285A1 (en) 2021-05-17 2022-05-17 Formulations of psilocybin

Publications (2)

Publication Number Publication Date
JP2024522065A JP2024522065A (ja) 2024-06-11
JP2024522065A5 true JP2024522065A5 (https=) 2025-03-25

Family

ID=82019233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571283A Pending JP2024522065A (ja) 2021-05-17 2022-05-17 シロシビンの製剤

Country Status (7)

Country Link
US (1) US20240261306A1 (https=)
EP (1) EP4340809A1 (https=)
JP (1) JP2024522065A (https=)
KR (1) KR20240009433A (https=)
AU (1) AU2022277515B2 (https=)
CA (1) CA3216799A1 (https=)
WO (1) WO2022243285A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240074434A1 (en) * 2019-04-12 2024-03-07 Jeffrey Hanson Robbins Composition including effervescent agents, biostimulant, nutrient, and pesticide
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
IL315086A (en) * 2022-06-09 2024-10-01 Diamond Therapeutics Inc Amorphous (A-polymorphic) psilocybin
WO2023247665A1 (en) * 2022-06-22 2023-12-28 Cybin Irl Limited Solid dispersions of psilocybin
WO2024031152A1 (en) * 2022-08-12 2024-02-15 Woke Pharmaceuticals Pty Ltd Process for improving powder flow characteristics of a crystalline compound
AU2023377801A1 (en) * 2022-11-07 2025-06-19 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof
KR20260013222A (ko) * 2023-05-24 2026-01-27 실로라 인코퍼레이티드 트립타민 유도체를 함유하는 제제 및 그의 용도
TW202529749A (zh) * 2023-10-11 2025-08-01 義大利帕多瓦大學 具有賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）及賽洛辛（ｐｓｉｌｏｃｉｎ）衍生物之組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2009094431A2 (en) * 2008-01-23 2009-07-30 Ams Research Corporation Inflatable medical implant system
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP7502308B2 (ja) * 2019-01-18 2024-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固体投与形態を製造する方法および固体投与形態
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20220304980A1 (en) * 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Similar Documents

Publication Publication Date Title
JP2024522065A5 (https=)
JP2023540017A5 (https=)
JP2022523786A5 (https=)
JP6758677B2 (ja) グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
JP2025505745A5 (https=)
KR101455548B1 (ko) 비정형 항정신병약 및 taar1 작용제를 포함하는 조합물
JP7051638B2 (ja) エスシタロプラム医薬組成物
TW201302705A (zh) 使用選擇性ｂｃｌ－２抑制劑之治療方法
CN1420776A (zh) 环氧合酶－2活性的抑制
JP2013544850A5 (https=)
TW200522944A (en) CB1 modulator compounds
JPH08208471A (ja) 薬物反応の増強作用
JP2025510942A5 (https=)
JP2022538817A5 (https=)
TW202220965A (zh) 用於心理疾患或心理增強之２－胺基茚滿化合物
JP2023523770A5 (https=)
JP2025506504A5 (https=)
JP2005508872A5 (https=)
US20110104186A1 (en) Small molecule immunopotentiators and assays for their detection
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
WO2016101898A1 (zh) 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
Farrokhi et al. Development of acute transverse myelitis following COVID-19 infection: a review on the potential pathways
WO2021194991A1 (en) Use of losmapimod for treatment of covid-19
JP2022527865A5 (https=)
TW200800148A (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient